Dextromethorphan and an oxidase inhibitor for treating intractable conditions
Patent 5863927 Issued on January 26, 1999. Estimated Expiration Date: 
September 19, 2016. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
September 19, 2016. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesMethod and composition of reducing pain Method for enhancing the systemic delivery of dextromethorphan for the treatment of neurological disorders Method for reducing emotional lability Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan Method for the treatment of chronic pain Use of dextromethorphan and an oxidase inhibitor to treat dermatitis Method for the treatment of pain Patent #: 5502058 InventorsAssigneeApplicationNo. 464792 filed on 09/19/1996US Classes:514/289, Two of the cyclos share at least three ring members (i.e., bridged) (e.g., morphinans, etc.)514/305, Quinuclidines (including unsaturation)514/491, With an additional active ingredient514/649, Amino nitrogen attached to aryl ring or aryl ring system by an acyclic carbon or acyclic chain514/651, Ether oxygen is part of the chain514/652, Alkanol group only between the amino nitrogen and an ether oxygen which is bonded directly to the aryl ring or aryl ring system (i.e., aryloxy alkanol amines)514/654The chain consists of two or more carbons which are unsubtituted or have acyclic hydrocarbyl substituents onlyExaminersPrimary: Spivack, Phyllis G.Attorney, Agent or FirmInternational ClassesA61K 031/44A61K 031/265 A61K 031/135 AbstractMethods are disclosed for increasing the effectiveness of dextromethorphan in treating chronic or intractable pain, for treating tinnitus and for treating sexual dysfunction comprising administering dextromethorphan in combination with a therapeutically effective dosage of a debrisoquin hydroxylase inhibitor. A preferred combination is dextromethorphan and the oxidative inhibitor quinidine.Other References
Field of SearchTwo of the cyclos share at least three ring members (i.e., bridged) (e.g., morphinans, etc.)Quinuclidines (including unsaturation) With an additional active ingredient Alkanol group only between the amino nitrogen and an ether oxygen which is bonded directly to the aryl ring or aryl ring system (i.e., aryloxy alkanol amines) The chain consists of two or more carbons which are unsubtituted or have acyclic hydrocarbyl substituents only Amino nitrogen attached to aryl ring or aryl ring system by an acyclic carbon or acyclic chain Ether oxygen is part of the chain | |
